Payment overview · 2025
General Payments
$211.72
10 reported records · 6 companies
Healthcare provider profile · identity verified
Eric Michael Davied, MD
Allopathic & Osteopathic Physicians|Family Medicine · NEW BRAUNFELS, TX · NPI 1902303696
Verified facts
What the public records show
CMS Open Payments records show Eric Michael Davied, MD received $211.72 in general payments during 2025 across 10 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 46.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 22824 records involving 7320 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tezspire by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $98.49 | 46.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.23 | 14.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.12 | 12.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.24 | 11.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.16 | 8.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.48 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $211.72 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $98.49 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.23 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.23 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.12 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 22824 supporting records · 7320 recipient NPIs · example record 1226871881 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 549 | 166 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 456 | 150 |
| Losartan Potassium | Losartan Potassium | 389 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 244 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 209 | 76 |
| Gabapentin | Gabapentin | 206 | 85 |
| Lisinopril | Lisinopril | 206 | 70 |
| Alendronate Sodium | Alendronate Sodium | 189 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 65 |
| Metformin Hcl Er | Metformin Hcl | 161 | 57 |
| Omeprazole | Omeprazole | 158 | 49 |
| Metformin Hcl | Metformin Hcl | 140 | 39 |
| Trazodone Hcl | Trazodone Hcl | 133 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 53 |
| Prednisone | Prednisone | 118 | 64 |
| Glipizide | Glipizide | 115 | 33 |
| Ozempic | Semaglutide | 105 | 19 |
| Furosemide | Furosemide | 103 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 28 |
| Celecoxib | Celecoxib | 86 | 35 |
| Carvedilol | Carvedilol | 85 | 31 |
| Ezetimibe | Ezetimibe | 79 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 41 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 48 |
| Eliquis | Apixaban | 67 | 20 |
| Sertraline Hcl | Sertraline Hcl | 65 | 22 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 62 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 27 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 59 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 58 | 22 |
| Jardiance | Empagliflozin | 58 | 14 |
| Montelukast Sodium | Montelukast Sodium | 56 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 20 |
| Memantine Hcl | Memantine Hcl | 49 | 18 |
| Donepezil Hcl | Donepezil Hcl | 47 | 18 |
| Meloxicam | Meloxicam | 47 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 16 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Simvastatin | Simvastatin | 43 | 11 |
| Allopurinol | Allopurinol | 42 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 15 |
| Propranolol Hcl | Propranolol Hcl | 41 | 13 |
| Rybelsus | Semaglutide | 41 | 12 |
| Finasteride | Finasteride | 40 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 13 |
| Potassium Chloride | Potassium Chloride | 39 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 13 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 37 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | 16 |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Famotidine | Famotidine | 35 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 31 |
| Buspirone Hcl | Buspirone Hcl | 34 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 33 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 16 |
| Ketoconazole | Ketoconazole | 30 | 20 |
| Mirtazapine | Mirtazapine | 29 | 11 |
| Spironolactone | Spironolactone | 28 | 13 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Topiramate | Topiramate | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 20 |
| Estradiol | Estradiol | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Nystatin | Nystatin | 18 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 12 |
| Ciclopirox | Ciclopirox | 16 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 12 |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 11 |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tezspire | Tezepelumab-Ekko | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $211.72 · 10 records | Bayer Healthcare Pharmaceuticals Inc. | AREXVY, Cologuard Collection Kit, INSPIRE, KISUNLA, Kerendia, Repatha, SHINGRIX | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error